Dissemin is shutting down on January 1st, 2025

Published in

Oxford University Press, Open Forum Infectious Diseases, 5(7), 2020

DOI: 10.1093/ofid/ofaa076

Links

Tools

Export citation

Search in Google Scholar

Hyaluronidase-Facilitated High-Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T-Cell Lymphopenia

Journal article published in 2020 by Rachel J. Cruz, Joseph F. Dasso ORCID, Carla Duff ORCID, Diane Krasnopero, Zsofia Long, Maryssa Ellison, Daime Nieves, Panida Sriaroon ORCID, Alfred Asante-Korang ORCID, Jolan E. Walter ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
White circle
Published version: policy unclear
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract We treated three pediatric cardiac transplant patients with chronic parvovirus viremia with high-dose intravenous immunoglobulin (HD-IVIG). One patient with severe T-cell lymphopenia suffered recurrent viremia and aseptic meningitis, which resolved remarkably when he was switched to high-dose hyaluronidase-facilitated subcutaneous immunoglobulin (HD-SCIG-Hy). We discuss the advantages of HD-SCIG-Hy vs HD-IVIG treatment for similar cases.